全文获取类型
收费全文 | 2593958篇 |
免费 | 187235篇 |
国内免费 | 7463篇 |
专业分类
耳鼻咽喉 | 34876篇 |
儿科学 | 86750篇 |
妇产科学 | 73331篇 |
基础医学 | 363423篇 |
口腔科学 | 70357篇 |
临床医学 | 234670篇 |
内科学 | 513413篇 |
皮肤病学 | 62918篇 |
神经病学 | 213299篇 |
特种医学 | 100225篇 |
外国民族医学 | 741篇 |
外科学 | 389085篇 |
综合类 | 52609篇 |
一般理论 | 978篇 |
预防医学 | 196510篇 |
眼科学 | 57201篇 |
药学 | 188446篇 |
8篇 | |
中国医学 | 5159篇 |
肿瘤学 | 144657篇 |
出版年
2019年 | 20288篇 |
2018年 | 28862篇 |
2017年 | 22370篇 |
2016年 | 25923篇 |
2015年 | 29186篇 |
2014年 | 40285篇 |
2013年 | 60256篇 |
2012年 | 80123篇 |
2011年 | 84360篇 |
2010年 | 50835篇 |
2009年 | 48996篇 |
2008年 | 78912篇 |
2007年 | 83719篇 |
2006年 | 85435篇 |
2005年 | 81585篇 |
2004年 | 78608篇 |
2003年 | 75849篇 |
2002年 | 73142篇 |
2001年 | 128186篇 |
2000年 | 131000篇 |
1999年 | 109787篇 |
1998年 | 29610篇 |
1997年 | 26195篇 |
1996年 | 26427篇 |
1995年 | 27228篇 |
1994年 | 24932篇 |
1993年 | 23286篇 |
1992年 | 85058篇 |
1991年 | 81535篇 |
1990年 | 78724篇 |
1989年 | 75997篇 |
1988年 | 69402篇 |
1987年 | 67952篇 |
1986年 | 63500篇 |
1985年 | 60466篇 |
1984年 | 44883篇 |
1983年 | 37847篇 |
1982年 | 22370篇 |
1981年 | 19905篇 |
1979年 | 38889篇 |
1978年 | 27363篇 |
1977年 | 23146篇 |
1976年 | 21376篇 |
1975年 | 22723篇 |
1974年 | 26697篇 |
1973年 | 25295篇 |
1972年 | 23697篇 |
1971年 | 21913篇 |
1970年 | 20139篇 |
1969年 | 19388篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Adam H. Fox MD MS Mizuki Nishino MD Raymond U. Osarogiagbon MBBS M. Patricia Rivera MD Lauren S. Rosenthal MPH Robert A. Smith PhD Farhood Farjah MD Lynette M. Sholl MD Gerard A. Silvestri MD MS Bruce E. Johnson MD 《CA: a cancer journal for clinicians》2023,73(4):358-375
Advances in biomarker-driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and pose new challenges for equitable care delivery. Over the last decade, the continuing development of new biomarker-driven therapies and evolving indications for their use have intensified the importance of interdisciplinary communication and coordination for patients with or suspected to have lung cancer. Multidisciplinary teams are challenged with completing comprehensive and timely biomarker testing and navigating the constantly evolving evidence base for a complex and time-sensitive disease. This guide provides context for the current state of comprehensive biomarker testing for NSCLC, reviews how biomarker testing integrates within the diagnostic continuum for patients, and illustrates best practices and common pitfalls that influence the success and timeliness of biomarker testing using a series of case scenarios. 相似文献
2.
3.
4.
Mahmut Gümüş MD Chieh-I Chen MPH Cristina Ivanescu PhD Saadettin Kilickap MD Igor Bondarenko MD Mustafa Özgüroğlu MD Miranda Gogishvili MD Haci M. Turk MD Irfan Cicin MD James Harnett PharmD Vera Mastey MS Ulrike Naumann MS Matthew Reaney MS Gerasimos Konidaris MS Medha Sasane PhD Keri J. S. Brady PhD Siyu Li PhD Giuseppe Gullo MD Petra Rietschel MD Ahmet Sezer MD 《Cancer》2023,129(1):118-129
5.
6.
7.
8.
Psychological mobile app for patients with acute myeloid leukemia: A pilot randomized clinical trial
Areej El-Jawahri MD Marlise R. Luskin MD Joseph A. Greer PhD Lara Traeger PhD Mitchell Lavoie BS Dagny Marie Vaughn BS Stephanie Andrews BS Daniel Yang BS Kofi Y. Boateng BS Richard A. Newcomb MD Nneka N. Ufere MD Amir T. Fathi MD Gabriela Hobbs MD Andrew Brunner MD Gregory A. Abel MD Richard M. Stone MD Daniel J. DeAngelo MD PhD Martha Wadleigh MD Jennifer S. Temel MD 《Cancer》2023,129(7):1075-1084
9.
Cynthia S. E. Hendrikse MD Phyllis van der Ploeg MD PhD Nienke M. A. van de Kruis MD Jody H. C. Wilting MD Floor Oosterkamp BSc Pauline M. M. Theelen MSc Christianne A. R. Lok MD PhD Joanne A. de Hullu MD PhD Huberdina P. M. Smedts MD PhD M. Caroline Vos MD PhD Brenda M. Pijlman MD Loes F. S. Kooreman MD Johan Bulten MD PhD Marjolein H. F. M. Lentjes-Beer MD PhD Steven L. Bosch MD PhD Anja van de Stolpe MD PhD Sandrina Lambrechts MD PhD Ruud L. M. Bekkers MD PhD Jurgen M. J. Piek MD PhD 《Cancer》2023,129(9):1361-1371
Background
Advanced low-grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.Methods
Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.Results
Patients who had normal ER STP activity had a progression-free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p < .001). Unlike ER histoscores, PR histoscores were strongly correlated to the ER STP activity and thus to PFS.Conclusions
Aberrant low and very high functional ER STP activity and low PR histoscores in patients with LGOC indicate decreased response to AHT. ER IHC is not representative of functional ER STP activity and is not related to PFS. 相似文献10.